Corey N. Fishman
Chief Executive Officer
Corey Fishman has served as Chief Executive Officer since late 2015 when the company was formed. From 2010 to 2015, Mr. Fishman served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. overseeing all aspects of finance and administration, manufacturing, business development, strategy, international operations and portfolio optimization. While at Durata, he raised substantial capital, including a successful IPO and secondary public offering. Mr. Fishman also led the negotiation and sale of the company to Actavis plc.
Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus company from 2008 to 2010. From 2002 to 2008, Mr. Fishman served in a leadership role at MedPointe Healthcare, Inc., a private equity backed specialty pharmaceutical company and became the Chief Financial Officer in 2006. Mr. Fishman had responsibility for finance and administration, portfolio optimization, manufacturing, strategy and business development. He led the development and implementation of a new strategic plan, which involved raising capital, restructuring debt, accelerating the growth of existing commercial assets and developing multiple line extensions to enhance future value, culminating in the successful sale of the company to Meda AB. From 1994 to 2002, Mr. Fishman held roles of increasing responsibility in both mid-size and large pharma.
Mr. Fishman serves on the board of Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs.
Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University.
Michael Dunne, MD
Chief Scientific Officer
Michael Dunne, MD has served as Chief Scientific Officer since late 2015 when the company was formed. Prior to that, Dr. Dunne was the Chief Medical Officer of Durata Therapeutics, Inc. from 2009 until its acquisition by Actavis plc in 2014 and remained in a leadership role as part of the Actavis integration efforts to ensure successful transition of all priority development activities until 2015. From 1992 to 2009, Dr. Dunne served in a variety of roles in connection with the clinical development of numerous infectious disease compounds at Pfizer Inc., including as the Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. Dr. Dunne holds a BA in Economics from Northwestern University and an MD from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.
Judith M. Matthews
Chief Financial Officer
Judy Matthews has served as Chief Financial Officer since late 2015 when the company was formed. From 2012 to 2015, Ms. Matthews served as VP of Finance at Durata Therapeutics, Inc. until its acquisition by Actavis plc. From 2009 to 2012, Ms. Matthews was Head of Financial Planning & Analysis at Bally Total Fitness. From 2004 to 2008, Ms. Matthews served as VP of Finance for the Sterno Group, a subsidiary of Blyth, Inc. Ms. Matthews holds a BA in Accounting from the University of Illinois at Urbana-Champaign and a Master of Management in Finance and Marketing from the Kellogg School of Management at Northwestern University.
Chief Commercial Officer
Jeff Schaffnit joined Iterum as the Chief Commercial Officer in early 2018. Mr. Schaffnit brings to Iterum more than 15 years of experience in pharmaceutical and biotech sales and marketing. Prior to joining Iterum, he was Group Vice President and Head of Patient Engagement at Shire, leading a large team focused on patient services and advocacy across the entire rare disease portfolio. Previously, Mr. Schaffnit was Group Vice President and Head of US Hematology for Baxalta and Baxter. In this role, Mr. Schaffnit was the U.S. commercial leader of the company's market leading Hematology business. Mr. Schaffnit spent 10 years at Abbott in several commercial leadership roles including General Manager of the company's anti-infective business. Mr. Schaffnit holds a BS in Chemical Engineering from the University of Illinois at Urbana-Champaign and a Master of Business Administration in Finance and Strategy from the Kellogg School of Management at Northwestern University.
Benjamin M. Pe
Vice President Operations
Ben Pe has served as VP Operations since late 2015 when the company was formed. From 2010 to 2015, Mr. Pe led numerous corporate and commercial functions at Durata Therapeutics, Inc. including HR, finance, commercial/sales operations, sales training, market research and business analytics as Executive Director, Commercial Operations and Analytics until Durata’s acquisition by Actavis plc. From 2008 to 2010, Mr. Pe served as Senior Director, Business Development of Ganic Pharmaceuticals, Inc. From 2002 to 2008, Mr. Pe served as Director of Marketing and Director, Business Development and Operations of MedPointe Healthcare, Inc. until its acquisition by Meda AB. Mr. Pe holds a BS in Finance from the University of Illinois at Urbana-Champaign and a Master of Management in Marketing, Finance and International Business from the Kellogg School of Management at Northwestern University.
Sailaja Puttagunta, MD
Vice President Development
Sailaja Puttagunta, MD joined Iterum Therapeutics in early 2016 as VP, Development. Prior to joining Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at Allergan from early 2015 and was the VP of Development and Medical Affairs at Durata Therapeutics, Inc. prior to its acquisition by Actavis plc. From 2006 to 2012, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at Pfizer Inc. Dr. Puttagunta has over 17 years of clinical, academic and research experience in medicine and in the sub-specialty of infectious diseases. She graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an MS in Biochemistry from the New York University School of Medicine.
John J. White
Vice President Business Development & Supply Chain
John White has served as VP Business Development & Supply Chain since late 2015 when the company was formed. From 2014 to 2015, Mr. White served as VP of Business Development & Licensing for Durata Therapeutics, Inc. until its acquisition by Actavis plc. From 2013 to 2014, Mr. White led the U.S. injectable marketing efforts for the Bristol-Myers Squibb/Astra Zeneca Diabetes Alliance. From 2003 to 2013, Mr. White served in a multitude of marketing, sales and operations leadership roles at Meda AB including General Manager of the company’s U.S. subsidiary, Wallace Pharmaceuticals. From 1995 to 2003, Mr. White held several roles of increasing responsibility at Schering-Plough. Mr. White holds a BA from Stonehill College.
Tom Loughman, PhD
Vice President and CMC Head
Tom Loughman, Ph.D. joined Iterum Therapeutics in late 2016 as VP, CMC and Manufacturing. Prior to joining Iterum, Tom served as Director of API Development at Ipsen from 2004 and was a member of their CMC and Dublin manufacturing site leadership teams. With over 20 years experience in the CMC field, Tom also held production management and product development leadership roles across Ipsen’s Technical Operations and R & D functions. He holds a Ph.D. in Pharmaceutics from Trinity College, Dublin and also holds a B.Sc. in Biotechnology from Dublin City University.